2027 ICD-10-CM Diagnosis Code E22.9Hyperfunction of pituitary gland, unspecified
ICD-10-CM Codes›E00–E89›E20-E35›E22
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Chronic Condition
E22.9 is a billable ICD-10-CM diagnosis code for hyperfunction of pituitary gland, unspecified. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 643 through 645. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 4 closely related codes. Coders also document this condition as hyperpituitarism. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Pituitary disorders.
E22.9 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 23 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 23, ESRD (V21) category 23, ESRD (V24) category 23, and RxHCC Part D (V08) category 43 for payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
E22.9 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Hyperpituitarism
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to E22.9: its own notes plus those printed at E22, block E20-E35, and Chapter 4. A note printed at a category, block or chapter applies to every code under it.
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Notes
General instructions on how these codes are used.
- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name E22.9, its category, or a range that includes it.
Code First 1
These codes say to code first a condition named in the note, and E22.9 is one of the conditions named.
- G63 Polyneuropathy in diseases classified elsewhere
Notes 1
These notes mention E22.9.
- Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseasesAll neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere. names E16-E31, which includes this code
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Hyperpituitarism E22.9
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Hyperpituitarism
disease of the glandular, anterior portion of the pituitary (pituitary gland, anterior) resulting in hypersecretion of adenohypophyseal hormones such as growth hormone; prolactin; thyrotropin; luteinizing hormone; follicle stimulating hormone ; and adrenocorticotropic hormone. hyperpituitarism usually is caused by a functional adenoma.
Patient EducationClinical
Pituitary Disorders
Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E22.9 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E22.9Overview
What is the ICD-10 code for hyperfunction of pituitary gland, unspecified?
The ICD-10-CM code for hyperfunction of pituitary gland, unspecified is E22.9 (sometimes written as E229). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is E22.9 (Hyperfunction of pituitary gland) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report hyperfunction of pituitary gland, unspecified on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does E22.9 group to?
When hyperfunction of pituitary gland, unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 644, 645, 643, with relative weights from 0.7461 to 1.6138 depending on complications. Higher weights mean higher Medicare reimbursement.
Is E22.9 a CC or MCC?
CMS lists E22.9 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 4 closely related codes in its exclusion list.
Can E22.9 be reported with a code from E24?
Not as a rule. The Excludes1 note at E22, which applies to E22.9, lists "Cushing's syndrome (E24.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
Does E22.9 risk-adjust for Medicare Advantage payment?
Not for Medicare Advantage. E22.9 mapped to HCC 23 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V21) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V24) category 23 (Other Significant Endocrine and Metabolic Disorders), and RxHCC Part D (V08) category 43 (Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders).
